[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351433-105":59,"doc-detail-351433-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","second-primary-cancers-following-hematologic-malignancies-epidemiology-pathobiology-and-clinical-management","Second primary cancers following hematologic malignancies - Epidemiology, pathobiology and clinical management","","Second primary cancers (SPCs) present an increasingly important clinical challenge for survivors of hematologic malignancies as therapies improve and survival lengthens. SPC development reflects a multifactorial process involving treatment-related injury, genetic susceptibility, immune dysregulation, and remodeling of the bone marrow microenvironment. This narrative review summarizes epidemiologic patterns, clarifies biological mechanisms such as therapy-induced genomic instability and clonal hematopoiesis, and outlines surveillance strategies and emerging biomarkers for early detection and risk stratification. It also considers multi-omics and precision medicine approaches and proposes personalized, translational, multidisciplinary management to reduce long-term SPC risk.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/second-primary-cancers-following-hematologic-malignancies-epidemiology-pathobiology-and-clinical-management/351433/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/second-primary-cancers-following-hematologic-malignancies-epidemiology-pathobiology-and-clinical-management/351433.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How are second primary cancers (SPCs) defined in patients with hematologic malignancies?","Question",{"text":112,"@type":113},"SPCs are newly diagnosed, histologically distinct malignant tumors appearing concurrently (within 6 months) or subsequently (after 6 months) after the initial hematologic malignancy, excluding metastatic disease and local recurrence.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What major factors drive SPC development after hematologic malignancies?",{"text":117,"@type":113},"SPC risk is shaped by treatment-related cellular damage, genetic susceptibility, immune dysregulation, and microenvironmental remodeling, including inflammatory signaling and bone marrow alterations.",{"name":119,"@type":110,"acceptedAnswer":120},"Which approaches are discussed for early detection and risk stratification of SPCs?",{"text":121,"@type":113},"The review covers current surveillance strategies and emerging biomarkers, and it highlights integrated multi-omics, tumor microenvironment profiling, and precision medicine as potential tools for SPC monitoring and prevention.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351433,1790156794,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","REVIEW  \nSecond primary cancers following hematologic malignancies: Epidemiology, pathobiology and clinical management  \nYueyue Pana, Hailing Yangb, Junliang Shaoa, Xinchen Qianga, and Qiong Wanga  \naDepartment of Laboratory Medicine, Wuxi Medical Center, Wuxi People’s Hospital, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, China; bKey Laboratory of Industrial Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, Wuxi, China  \nABSTRACT  \nSecond primary cancers (SPCs) pose an increasingly significant clinical challenge for survivors of hematologic malignancies, attributed to improved therapeutic outcomesand prolonged survival. The development of SPCs is influenced by a complex interplay of treatment-related factors, genetic susceptibility, immune dysregulation, and microenvironmental remodeling. This narrative review summarizes the epidemiological patterns of SPCs in survivors of hematologic malignancies and discusses the underlying biological mechanisms, including therapy-induced genomic instability, clonal hematopoiesis, inflammatory signaling, and alterations in the bone marrow microenvironment. Furthermore, we review current surveillance strategies and emerging biomarkers for early detection and risk stratification. Additionally, we discuss the potential contributions of integrated multi-omics approaches, tumor microenvironment profiling, and precision medicine strategies to SPC monitoring and prevention. Lastly, we outline future directions for clinicians and researchers, emphasizing the necessity for personalized surveillance programs, translational biomarker validation, and multidisciplinary management strategies to mitigate SPC risk in long-term survivors.  \nARTICLE HISTORY  \nReceived 7 November 2025 Revised 17 March 2026 Accepted 29 March 2026  \nKEYWORDS  \nHematological malignancies; second primary cancers; chimeric antigen receptor T-cell therapy; genetic susceptibility; multidisciplinary team  \nIntroduction  \nHematologic malignancies, which encompass leukemia, lymphoma, and multiple myeloma (MM), constitute a heterogeneous group of disorders originating from the blood and hematopoietic system. 1–3 Recent advances in antineoplastic therapies and earlier detection methods have significantly improved long-term survival rates among patients with these malignancies. However, an increasing number of survivors are developing second primary cancers (SPCs), defined as newly diagnosed, histologically distinct malignant tumors identified either concurrently (within 6 months) or subsequently (after 6 months) to the initial hematologic malignancy, excluding cases of metastatic disease and local recurrence.4–6 The emergence of SPCs is influenced by a complex interplay of germline genetic susceptibility, therapy-induced cellular damage, environmental exposures, and remodeling of the tumor microenvironment. Notably, the risk of developing SPCs appears to be higher in survivors of hematologic malignancies compared to those with solid tumors. Research on SPCs following hematologic malignancies remains fragmented, lacking standardized diagnostic criteria and consensus-based management strategies in clinical practice. This narrative review systematically synthesizes the current evidence on the epidemiology, pathogenic mechanisms, and clinical management ofSPCs after hematologic malignancies, aiming to provide a comprehensive reference for clinical practice and future research.  \nEpidemiology: a rising tide after the storm  \nSurvivors ofhematologic malignancies exhibit a significantly increased risk ofSPCs compared to the general population, with standardized incidence ratios (SIRs) ranging from 1.27 to 2.60, indicating a 10–14% heightened incidence risk (Table 1) .4,7,8 Population-based studies primarily provide broad risk estimates  \nCONTACT Qiong Wang  [wangqiong_john@163.com](wangqiong_john@163.com)  Wuxi Medical Center, Wuxi People’s Hospital, The Affiliated Wuxi People’s Ho","cbCaiayTylEt4oma","https://ap.wps.com/l/cbCaiayTylEt4oma","pdf",4196679,18,"English","# Introduction\n# Epidemiology: a rising tide after the storm\n# Pathobiology\n# Clinical management\n# Surveillance strategies and biomarkers\n# Future directions","[{\"question\":\"How are second primary cancers (SPCs) defined in patients with hematologic malignancies?\",\"answer\":\"SPCs are newly diagnosed, histologically distinct malignant tumors appearing concurrently (within 6 months) or subsequently (after 6 months) after the initial hematologic malignancy, excluding metastatic disease and local recurrence.\"},{\"question\":\"What major factors drive SPC development after hematologic malignancies?\",\"answer\":\"SPC risk is shaped by treatment-related cellular damage, genetic susceptibility, immune dysregulation, and microenvironmental remodeling, including inflammatory signaling and bone marrow alterations.\"},{\"question\":\"Which approaches are discussed for early detection and risk stratification of SPCs?\",\"answer\":\"The review covers current surveillance strategies and emerging biomarkers, and it highlights integrated multi-omics, tumor microenvironment profiling, and precision medicine as potential tools for SPC monitoring and prevention.\"}]","Second primary cancers following hematologic malignancies - Epidemiology, pathobiology and clinical management | PDF",1790094142,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d38e7657da39fbbffdfc9c28d603979.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f79bab3a4832b73833f614e1f2e3cb2.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48d66a5a3e7d9c8b85d07ba199b9d66d.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bfbc3efdefeef7e06369a9ad6e023553.webp",980,1306]